Corvus Pharmaceuticals: FDA Granted IND Application for COVID-19 Trial
The United States FDA granted approval of Corvus Pharmaceuticals (CRVS) investigational new drug (IND) application for a COVID-19 trial.
Corvus announced the beginning of the Phase 1 study that intends to enroll up to 30 patients. The . . .
This content is for paid subscribers.
Today’s Highlights
July 7, 2020
